January 2023: Notable Drug Approvals


Pharmacologic Class


More Information

Endocrine Disorders
Brenzavvy (bexagliflozin) Sodium-glucose cotransporter 2 inhibitor As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Brenzavvy Approved for Adults With Type 2 Diabetes
Neurologic Disorders
Leqembi (lecanemab-irmb) Amyloid beta-directed antibody. Treatment of Alzheimer disease. Leqembi Drug Monograph
Brukinsa (zanubrutinib) Small molecule inhibitor of Bruton tyrosine kinase For the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. Brukinsa Drug Monograph
Jaypirca (pirtobrutinib) Noncovalent inhibitor of BTK Treatment of adult patients with relapsed or refractory mantle cell lymphoma after at least 2 lines of systemic therapy, including a BTK inhibitor. Jaypirca Approved for Relapsed/Refractory Mantle Cell Lymphoma
Keytruda (pembrolizumab) Programmed death receptor-1 blocking antibody For adjuvant treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB, II, or IIIA non-small cell lung cancer. Keytruda Approved as Adjuvant Treatment for Stage IB, II, or IIIA NSCLC
Orserdu (elacestrant) Estrogen receptor antagonist Treatment of postmenopausal women or adult men with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy. Orserdu Approved for ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
Tukysa (tucatinib) Tyrosine kinase inhibitor In combination with trastuzumab for the treatment of adults with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. Tukysa Drug Monograph
Psychiatric Disorders
Rykindo (risperidone) Atypical antipsychotic Treatment of schizophrenia in adults, and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults. Rykindo Approved for Schizophrenia, Bipolar Disorder